Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey, discusses the impact of increases in drug prices on oncology stakeholders.
Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey, discusses the impact of increases in drug prices on oncology stakeholders.
Trascript
What is the impact of novel therapies on oncology stakeholders?
The whole challenge with healthcare these days is the total cost of care, and these new cancer therapies have really changed the cost paradigm. So, going from drugs that were hundreds or thousands of dollars to drugs that are hundreds of thousands of dollars has an impact on employers, it’s likely to raise the total cost of care, certainly the patient out-of-pocket expense with high deductible plans can be a real factor. But, the biggest impact is really on hospitals and insurance providers because therapies that are administered in inpatient are often included within a DRG, and that cost obviously blows up what the traditional DRG is. For those that are outpatient, it’s an added cost to the insurers, and the ability to understand what those costs are in an appropriately priced product when they’re selling them, (ie passing them on to the ultimate payer). It’s a real revolution in the costs of understanding how to manage this kind of cost in the explosion of new therapies is a real challenge, and figuring that out is gonna be the next few year’s work.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More